The Federal Trade Commission (FTC), State of California, and Utah Division of Consumer Protection recently filed a sweeping complaint against telemedicine company Hims & Hers Health, Inc., using federal and state consumer-protection laws to assert allegations against its direct-to-consumer telehealth business. The case is notable as regulators are not relying on a traditional health-privacy statute but rather general consumer-protection laws to challenge health-data advertising practices and aspects of Hims’s subscription model.

/PRNewswire/ -- On July 29, 2026, investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares slide about 14% lower on news that the FTC...

NEW YORK, NY - August 25, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. On July 29, 2026, the Federal Trade Commission (“FTC”), the People of the State of California through Los Angeles County Counsel and the Utah Division of Consumer Protection sued Hims & Hers in the Northern District of California. According to the FTC, the action alleges that Hims & Hers fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able…